Sarah Joanne Williams - 26 Jan 2026 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Principal Accounting Officer
Signature: /s/ Sarah Joanne Williams
Issuer symbol: ANTX
Transactions as of: 26 Jan 2026
Net transactions value: $0
Form type: 3
Filing time: 03 Feb 2026, 18:08:57 UTC
Next filing: 23 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Williams Sarah Joanne	Principal Accounting Officer	C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK	/s/ Sarah Joanne Williams	03 Feb 2026	0002108922

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ANTX	Common Stock						18,800	26 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ANTX	Stock Option (right to buy)							26 Jan 2026	Common Stock	21,875	$1.13	Direct	F2
holding	ANTX	Stock Option (right to buy)							26 Jan 2026	Common Stock	23,700	$2.07	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes the balance of (a) 10,938 RSUs which vest as follows: 1/4th of the RSUs vest in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (b) 11,850 RSUs which vest as follows: 1/16th of the RSUs vest in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. A total of 3,174 shares from the aggregate number of the RSUs issued under (a) and (b) above were sold to cover taxes and a total of 814 shares were sold on the open market.
F2	The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and become exercisable (rounded down to the nearest whole number of shares) monthly over four years from January 1, 2025 until fully vested and exercisable on January 1, 2029, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
F3	The shares subject to the option are exercisable and vest as follows: 1/4th of the shares vest and become exercisable (rounded down to the nearest whole number of shares) on the first anniversary of May 28, 2024, and 1/48th of the shares vest and become exercisable monthly (rounded down to the nearest whole number of shares) over the following three years until fully vested and exercisable on May 28, 2028, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.